The FDA on August 17, 2017 approved BESPONSA® for the treatment of adults with relapsed or refractory B-cell precursor Acute Lymphoblastic Leukemia (ALL). BESPONSA® is a product of Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
